Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Its Association With Comprehensive Genomic Profiling and/or Cell-Free DNA Results

BACKGROUND: Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1–3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothel...

Full description

Saved in:
Bibliographic Details
Published in:Cancer
Main Authors: Pal, Sumanta K., Bajorin, Dean, Dizman, Nazli, Hoffman-Censits, Jean, Quinn, David I., Petrylak, Daniel P., Galsky, Matthew D., Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard A., Soifer, Harris S., Li, Gary, Wang, Hao, Dambkowski, Carl L., Moran, Susan, Daneshmand, Siamak, Rosenberg, Jonathan E.
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515773/
https://ncbi.nlm.nih.gov/pubmed/32208524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32806
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items